Humana (HUM)

NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-09-04

$401.54-1.23%

Close 2026-09-04 · 1-day change

Standing thesis

The standing, falsifiable read: what has to stay true, and what would break it.

Compounder

Warn: Primary pillar under pressure — Maintain EPS guidance of at least $9.00 for FY 2026: EPS guidance $9.00 vs $9.00 target (lowered).

The bull case

Humana keeps its EPS guidance at $9.00 for 2026. It won a big Illinois Medicaid contract that should boost revenue and margins. The company also announced a share buyback program, showing strong capital allocation. Recent earnings beats support steady profit growth.

The bear case

EPS guidance is soft and behind targets. Net income declined sharply in late 2025. Management is volatile, and capital obligations have increased. These risks could pressure margins and growth.

What's priced in

The price is about 21% above our fair value near $322. Analysts expect 16% revenue growth. Our fair value is 24% above the Street median, reflecting confidence in Humana's growth and margin outlook.

What has to stay true

Effective share buyback program executionIntact
Capital AllocationsupportingSustained buyback activity per announced program · next 4 quarters (qualitative)
Breaks if: Buyback program is halted or materially reduced
Maintain EPS guidance of at least $9.00 for FY 2026Under Pressure
Management Executionprimary>=9.00 USD per share · FY26 (guidance)
Breaks if: EPS guidance falls below $9.00 for FY 2026
Revenue growth from Illinois Medicaid HealthChoice programUnder Pressure
Revenue Growthprimary>=15% YoY revenue growth · FY26 (qualitative)
Revenue growth falls below 15% YoY in FY26

Source: QuarterlyIQ research model· Written 2026-07-08· Health checked 2026-09-04· Version 1· Status: Warn· Reviewed when the evidence changes

This is not a price target or investment advice.

Current Outlook

Week of Sep 5, 2026

A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.

HUM's long-term thesis reflects a mix of strong recent performance and ongoing challenges.

What kind of bet this is

This investment represents a durable compounder with a focus on healthcare services. The current thesis state is intact, supported by strong financial performance, but it faces volatility in management and regulatory challenges.

What's priced into Humana (HUM)

The valuation appears cheap compared to peers, with the market pricing in some fragility due to weak execution quality. The expectations gap is slightly negative, indicating that the market may not fully reflect the potential upside from improved performance.

What the fundamentals likely do

Fundamentals are likely to show mixed results as management focuses on maintaining earnings guidance and expanding service platforms. Recent financial performance has been strong, but risks remain elevated due to regulatory challenges and market conditions.

What Humana (HUM) hinges on

The thesis hinges on management's ability to raise guidance in the next quarter and the performance of sector bellwethers like UNH and CVS. Additionally, macroeconomic factors, such as job growth, will play a crucial role in shaping future outcomes.

What changed in the latest read

What changed

The most important moves since the prior daily snapshot.

Short-term · Daily

No material changes since the prior snapshot.

Mixed, the news cuts both ways. The latest earnings beat supports the read on HUM. However, next quarter's revenue guidance is below consensus, which weakens the outlook. The impact of Star Ratings on the Medicare Advantage business remains a concern.

as of 2026-09-04

See upcoming information that could change the risk

Review the evidence to watch, what would become a concern, and what would make it less concerning.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.